The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Outcomes of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with different new agents (NAs) sequence in post-docetaxel (DOC) setting: Final analysis from a multicenter Italian study.
 
Orazio Caffo
Honoraria - Astellas Pharma; Bayer; Janssen Oncology; Sanofi
 
Emilio Bria
No Relationships to Disclose
 
Ugo De Giorgi
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Janssen; Pfizer; Pierre Fabre; Sanofi
 
Marcello Tucci
No Relationships to Disclose
 
Luca Galli
No Relationships to Disclose
 
Lucia Fratino
No Relationships to Disclose
 
Sabrina Rossetti
No Relationships to Disclose
 
Roberto Iacovelli
No Relationships to Disclose
 
Giovanni Lo Re
No Relationships to Disclose
 
Claudia Mosillo
No Relationships to Disclose
 
Donatello Gasparro
No Relationships to Disclose
 
Pamela Francesca Guglielmini
No Relationships to Disclose
 
Azzurra Damiani
No Relationships to Disclose
 
Giuseppe Procopio
Honoraria - Amgen; Astellas Oncology; Pfizer
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Ipsen; Janssen; Novartis
Research Funding - Bayer; Novartis
 
Delia De Lisi
No Relationships to Disclose
 
Fiorella Ruatta
No Relationships to Disclose
 
Sarah Scagliarini
No Relationships to Disclose
 
Maddalena Donini
No Relationships to Disclose
 
Isabella Sperduti
No Relationships to Disclose
 
Umberto Basso
Consulting or Advisory Role - Janssen; Novartis; Pfizer; Sanofi
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis; Pfizer; Pierre Fabre; Sanofi